Beyond Standard Inhalers
For most people with asthma, inhaled medications control symptoms effectively, but a subset have severe, difficult-to-control disease that persists despite maximal standard therapy. For this population, biologic drugs — sophisticated medications that target specific molecules driving inflammation — have transformed treatment, offering meaningful relief for patients who previously faced frequent exacerbations, oral steroid dependence, and significantly impaired quality of life.
Precision Targeting of Inflammation
Unlike inhaled steroids that broadly suppress airway inflammation, biologics target specific inflammatory pathways — certain antibodies block particular signaling molecules involved in the allergic and eosinophilic inflammation that drives many cases of severe asthma. This precision approach means treatment can be matched to a patient specific inflammatory profile, identified through blood and other testing, allowing more individualized and effective therapy than one-size-fits-all approaches.
Who Benefits and What Changes
Patients on appropriate biologic therapy often experience dramatically fewer exacerbations, reduced or eliminated need for oral steroids with their significant side effects, and improved lung function and quality of life. These medications require identifying the right inflammatory phenotype and are reserved for severe, uncontrolled disease rather than routine asthma. For appropriate candidates, they represent one of the most significant advances in asthma care in decades. Facilities can source respiratory supplies and pharmacy supplies from our catalog.
